Company Description
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women’s reproductive health needs in the United States and internationally.
The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation.
It also provides FemBloc, a non-surgical female permanent birth control solution. The company offers its products to gynecological physicians, related healthcare professionals, and women’s healthcare provider organizations.
Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
| Country | United States |
| Founded | 2004 |
| IPO Date | Jun 18, 2021 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 54 |
| CEO | Kathy Lee-Sepsick |
Contact Details
Address: 3950 Johns Creek Court, Suite 100 Suwanee, Georgia 30024 United States | |
| Phone | 770 500 3910 |
| Website | femasys.com |
Stock Details
| Ticker Symbol | FEMY |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $13.00 |
| CIK Code | 0001339005 |
| CUSIP Number | 31447E204 |
| ISIN Number | US31447E2046 |
| Employer ID | 11-3713499 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Kathy Lee-Sepsick M.B.A. | Founder, President, Chief Executive Officer and Director |
| Dov Elefant | Chief Financial Officer |
| John Canning | Chief Operating Officer |
| Jeremy Alexander Sipos | Chief Technology Officer |
| Mary An Merchant J.D., Ph.D. | Vice President of Counsel and Intellectual Property |
| Benjamin Dings | Vice President of Sales |
| Megan Eckerman | Senior Vice President of Global Marketing |
| Dr. Jeffrey Marcus M.D., M.S. | Chief Medical Advisor |
| Christine Thomas | Senior Vice President of Regulatory and Clinical Affairs |
| Dr. James H. Liu M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 24, 2026 | 8-K | Current Report |
| Jun 24, 2026 | 8-K | Current Report |
| Jun 5, 2026 | 8-K | Current Report |
| Jun 4, 2026 | 8-K | Current Report |
| May 13, 2026 | 8-K | Current Report |
| May 8, 2026 | 10-Q | Quarterly Report |
| May 8, 2026 | 8-K | Current Report |
| Apr 30, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 30, 2026 | ARS | Filing |
| Apr 30, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |